Until recently, the regulatory landscape for stem cell and regenerative therapies has been at times restrictive, allowing patients to access stem cell interventions only under the Expanded Access to Investigational Drugs for Treatment Use program. Treatments are eligible under this program if they are undergoing  testing a clinical trial and are subject to approval by the FDA. Three-quarters of the states in the nation have passed “Right to Try” legislation, however, which allows terminally ill patients to receive experimental therapies that have passed 1 trials without seeking FDA approval.